Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Advanced Development of Patient Ascites Therapeutic Response Biosensors

Award Number: R33CA291166
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2025
PERIOD OF PERFORMANCE END DATE: 02/29/2028

Group Awards By:

View Award Description

Advanced Development of Patient Ascites Therapeutic Response Biosensors - PROJECT SUMMARY/ABSTRACT: Overcoming cancer drug resistance is a major unmet clinical need across many cancer types, including difficult-to-treat diseases such as gastroesophageal (GEA) and ovarian cancer. In principle, it should be possible to prioritize therapeutic regimen(s) given the molecular and cellular classification of such tumors. However, two bottlenecks prevent sustained progress. First, biopsies from refractory disease are challenging to routinely obtain and evaluate, especially in community settings, both for clinical and research purposes. Second, even when such material is procured, it remains challenging to accurately predict therapeutic sensitivities from baseline tumor and immune profiling. Further, intra-tumoral heterogeneity can render distinct biopsies taken from the same patient tumor discordant. In this revised IMAT proposal we capitalize on the clinical observation that upwards of 40% of GEA and 70% of ovarian patients develop peritoneal carcinomatosis and ascites, a plentiful, heterogenous and molecularly representative sample format that is easily accessible since routine drains occur during patient care. However, in standard practice, such drains are discarded with little detailed evaluation or analysis - and given highly variable tumor purities, bulk profiling is rarely informative. To address these challenges, we have developed the first generation of AscitesPredict, a zero passage ‘ex vivo tumor biosensor’ technology that uses single cell technologies to evaluate cell identities and therapeutic sensitivities during a 5 day period in which viability is preserved. AscitesPredict utilizes high dimensional label- free single cell image-based morphological profiling and machine learning applied to brightfield microscopy which can be collected continuously. Thus far, we have developed AscitesPredict by profiling over 35 samples, made initial assessments of technological reproducibility, and have optimized initial workflows. In this revised proposal we take the next steps to harden the technology to prepare it for wider deployment in research settings to support preclinical drug development and in clinical settings as a functional diagnostic. Our goals will be achieved via two Specific Aims. First, we will evaluate real world technical and biological performance characteristics. Second, we will demonstrate broader applicability of drug response measurements by enabling the evaluation of new classes of therapeutic agents including those that impact immune and stromal cells and improve the predictive accuracy of a wider diversity of cellular death pathways beyond apoptosis to support preclinical therapeutic studies. At the conclusion of this project, the technology will be poised for wider deployment across research settings and be sufficiently hardened to enable the launch of a third phase of evaluation clinically as a companion diagnostic. Our focus both on major medical centers and patients treated in the community will enable the widest, most equitable impact possible. 1


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $419,133 )
2025	2025	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	77 MASSACHUSETTS AVE	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Cancer Detection and Diagnosis Research	000	1	2/20/2025	NEW	$419,133
														Subtotal = $419,133

Grand Total All Awards = $419,133

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Advanced Development of Patient Ascites Therapeutic Response Biosensors

Award Number: R33CA291166

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2025

PERIOD OF PERFORMANCE END DATE: 02/29/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer